The highest-concentration formulation in the ExoPearl™ range. 20 cryo-formed spheres per vial delivering ≥ 200 billion HMSC-derived exosomes for intravenous administration under physician oversight. Lot-traceable. CoA per batch.
Every BEXO·PRIME vial is characterised per batch with NTA and TEM. Full documentation and lot traceability supplied with each order.
Peer-reviewed literature documents investigational interest in IV-administered HMSC-derived exosomes across the following domains. BEXO·PRIME provides the concentration required for systemic IV protocols.
For longevity clinics and integrative medicine practices operating physician-supervised IV protocols. Peer-reviewed literature documents investigational interest in systemically delivered HMSC exosomes for regenerative signalling across multiple tissue compartments. BEXO·PRIME provides the highest ExoPearl™ concentration available - ≥ 200 billion exosomes per vial.
Peer-reviewed literature documents investigational interest in IV-administered HMSC exosomes for systemic immunomodulation, including M1→M2 macrophage transition and modulation of pro-inflammatory cytokine cascades. BEXO·PRIME carries the standard HMSC-EV cargo profile, including tetraspanins, growth factors, and macrophage mediators confirmed via NTA and TEM per batch.
For regenerative medicine centres requiring high-concentration exosome biologics for clinical protocol development. BEXO·PRIME is lot-traceable with full CoA documentation, supporting the rigour expected by physician-led practices operating under local clinical and regulatory frameworks.
BEXO·PRIME delivers 10× the exosome count of a standard 2-sphere vial, in a single clinical-format package designed for IV protocols.